Senate Rejects Sanders' Amendment to Lower Prescription Drug Prices

In a recent Senate vote, an amendment proposed by Senator Bernie Sanders (I-Vt.) aimed at reducing prescription drug prices in the United States was rejected. The amendment sought to ensure that Americans would not pay more for medications than citizens in Canada, the United Kingdom, Germany, France, and Japan. The vote resulted in a tie at 49-49, failing to meet the 60 votes required to attach the proposal to the budget resolution. Notably, only two Republicans, Senators Josh Hawley (Mo.) and Dan Sullivan (Alaska), supported the amendment alongside all present Democrats.

The HillTruthOut

The proposed amendment was part of a broader budget reconciliation package intended to fund the Department of Homeland Security and its agencies, including Immigration and Customs Enforcement (ICE) and Customs and Border Protection (CBP). Sanders emphasized the urgency of addressing high drug prices, stating that one in four Americans cannot afford their prescriptions, leading to thousands of deaths annually. He referenced President Donald Trump's previous call for a "most favored nation" drug policy during his State of the Union address, which aimed to align U.S. drug prices with those in other developed nations.

TruthOut

This amendment follows Sanders' introduction of the Prescription Drug Price Relief Act, which mandates federal health officials to review brand-name drugs for excessive pricing annually. If a drug is found to be priced excessively compared to median prices in the aforementioned countries, the exclusivity granted to its sponsor could be voided. The criteria for excessive pricing include considerations of development costs and patient population size.

TruthOut

In his remarks on the Senate floor, Sanders stated, “The American people pay by far the highest prices in the world for prescription drugs... This amendment is very simple.” He criticized the overwhelming opposition from Senate Republicans, who largely rejected a policy that had previously garnered support from Trump. The failure of the amendment has been viewed as a setback for efforts to reform drug pricing in the U.S.

TruthOut

The rejection of Sanders' amendment has drawn criticism from various quarters, particularly from advocates for healthcare reform who argue that the current system disproportionately affects low-income Americans. Experts have pointed out that without congressional action, Trump's executive order aimed at lowering drug prices lacks enforceability, rendering it ineffective. Critics argue that the Senate Republicans' stance reflects a broader reluctance to address the pharmaceutical industry's pricing practices.

TruthOut

While the amendment was supported by a minority of Republicans, the majority of the Senate GOP opposed it, raising questions about the political dynamics surrounding healthcare reform. The exact implications of this vote on future drug pricing legislation remain unclear, as the Senate continues to navigate complex budgetary discussions.

TruthOut

• “The American people pay by far the highest prices in the world for prescription drugs, and the result is 1 out of 4 Americans cannot afford the prescriptions that their doctors write, and thousands die every year as a result,” — Bernie Sanders, U.S. Senator

The Hill

• “This amendment is very simple. It would prevent pharmaceutical companies from charging more for prescription drugs in the United States than they do in Canada, the U.K., Germany, France and Japan.” — Bernie Sanders, U.S. Senator

The Hill

The rejection of the Sanders amendment highlights ongoing challenges in the U.S. healthcare system, particularly regarding prescription drug pricing, and sets the stage for continued debate in Congress.

The Hill